DE60044092D1 - Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika - Google Patents

Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika

Info

Publication number
DE60044092D1
DE60044092D1 DE60044092T DE60044092T DE60044092D1 DE 60044092 D1 DE60044092 D1 DE 60044092D1 DE 60044092 T DE60044092 T DE 60044092T DE 60044092 T DE60044092 T DE 60044092T DE 60044092 D1 DE60044092 D1 DE 60044092D1
Authority
DE
Germany
Prior art keywords
normal cells
chemotherapeutics
anticancer
protection
cytotoxic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044092T
Other languages
English (en)
Inventor
Stephen C Cosenza
M V Reddy
Premkumar E Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Application granted granted Critical
Publication of DE60044092D1 publication Critical patent/DE60044092D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/02Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/14Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/16Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
DE60044092T 1999-10-12 2000-10-11 Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika Expired - Lifetime DE60044092D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15912399P 1999-10-12 1999-10-12
PCT/US2000/028250 WO2001026645A1 (en) 1999-10-12 2000-10-11 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Publications (1)

Publication Number Publication Date
DE60044092D1 true DE60044092D1 (de) 2010-05-12

Family

ID=22571170

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044092T Expired - Lifetime DE60044092D1 (de) 1999-10-12 2000-10-11 Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika

Country Status (8)

Country Link
EP (1) EP1223923B1 (de)
JP (1) JP4780885B2 (de)
AT (1) ATE462423T1 (de)
AU (1) AU780844B2 (de)
CA (1) CA2387539C (de)
DE (1) DE60044092D1 (de)
IL (1) IL149064A0 (de)
WO (1) WO2001026645A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548553B2 (en) 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
EP1173160B1 (de) * 1999-04-02 2005-06-22 Temple University of the Commonwealth System of Higher Education (e)-styrylsulfone als krebsbestreitende mittel
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
EP1328511B1 (de) 2000-10-05 2010-03-24 Temple University of the Commonwealth System of Higher Education Substituierte (e)-styrylbenzylsulfone zur behandlung proliferativer erkrankungen
US6833480B2 (en) 2001-02-27 2004-12-21 Temple University - Of The Commonwealth System Of Higher Education (Z)-styrylbenzylsulfones and pharmaceutical uses thereof
AU2002305942B2 (en) * 2001-02-28 2006-10-26 Onconova Therapeutics, Inc. Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
CA2477232C (en) * 2002-02-28 2011-07-19 Temple University - Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
EP1689706B1 (de) * 2003-11-14 2017-01-11 Temple University - Of The Commonwealth System of Higher Education Alpha, beta-ungesättigte sulfoxide zur behandlung von proliferativen erkrankungen
WO2007016201A2 (en) * 2005-07-29 2007-02-08 Onconova Therapeutics, Inc. FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
EP2091527B1 (de) * 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfid-, sulfoxid- und sulfon-chalcon-analoge, derivate davon und therapeutische anwendungen davon
WO2021007840A1 (zh) * 2019-07-18 2021-01-21 华夏生生药业(北京)有限公司 氨基甲酸酯取代的苯乙烯基砜类化合物及其制备方法和用途
CN111253935B (zh) * 2019-12-24 2022-12-13 安徽大学 一种双通道检测极性和粘度的双光子荧光探针及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
EP0439421A1 (de) * 1990-01-23 1991-07-31 Ciba-Geigy Ag Mikrobizide Mittel
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
IL135438A (en) * 1997-10-03 2005-12-18 Univ Temple Pharmaceutical compositions containing styrl sulfones and some such novel styryl sulfone compounds with anticancer activity

Also Published As

Publication number Publication date
WO2001026645A1 (en) 2001-04-19
JP4780885B2 (ja) 2011-09-28
JP2003511412A (ja) 2003-03-25
EP1223923A1 (de) 2002-07-24
IL149064A0 (en) 2002-11-10
AU1198901A (en) 2001-04-23
CA2387539A1 (en) 2001-04-19
ATE462423T1 (de) 2010-04-15
EP1223923A4 (de) 2007-09-05
AU780844B2 (en) 2005-04-21
CA2387539C (en) 2010-09-21
EP1223923B1 (de) 2010-03-31

Similar Documents

Publication Publication Date Title
DE60044092D1 (de) Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika
ATE406881T1 (de) Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
SV2002000248A (es) Composicion farmaceutica suministrando concentracion aumentada de la droga ref. pc10755ajtj/bb
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
SV2002000586A (es) Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b
WO2005044181A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
DOP2007000041A (es) Profarmacos mejorados de analogos de cc-1065
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
BRPI0716171B8 (pt) composto, composição farmacêutica e uso de um composto
UY28736A1 (es) Derivados de quinazolina
AR026560A1 (es) Recubrimiento
BRPI0907414A2 (pt) forma oral de dosagem farmacêutica contendo pelo menos dois medicamentos
PT2057139E (pt) Derivados de sulfureto de hidrogénio de fármacos antiinflamatórios não esteroidais
WO2009092278A8 (zh) 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
HRP20150678T1 (hr) Antitumorska aktivnost temsirolimusa kod papilarnog raka bubrežnih stanica
SI1615638T1 (sl) Uporaba derivatov 7-nitro-2,1,3-benzoksadiazola pri terapiji proti raku
WO2009088831A3 (en) Method of inhibiting abcg2 and other treatment methods
BR112021018525A2 (pt) Sistema de embalagem farmacêutica e método de fabricação de um sistema de embalagem farmacêutica
AR026004A1 (es) Pirroles substituidos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition